CN105902524A - Sublingual zolpidem tartrate pellicle and preparation method thereof - Google Patents
Sublingual zolpidem tartrate pellicle and preparation method thereof Download PDFInfo
- Publication number
- CN105902524A CN105902524A CN201610517942.6A CN201610517942A CN105902524A CN 105902524 A CN105902524 A CN 105902524A CN 201610517942 A CN201610517942 A CN 201610517942A CN 105902524 A CN105902524 A CN 105902524A
- Authority
- CN
- China
- Prior art keywords
- film
- zolpidemtar trate
- sublingual
- flavouring
- zolpidemtar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a sublingual zolpidem tartrate pellicle and a preparation method thereof, belonging to the fields of pharmacy and preparations. The sublingual zolpidem tartrate pellicle comprises zolpidem tartrate, a high-polymer film-forming material, a plasticizer, a penetration enhancer, a flavoring agent and other auxiliary materials. By adding the penetration enhancer, the velocity that a main drug penetrates through an in-vitro sublingual mucosa of an animal is obviously increased. The dosage form has the characteristics that the disintegration is rapid, the pellicle does not need to be taken with water, and the medicine taking compliance is good; and the pellicle is superior to most orally-taken soil preparations and is particularly applicable to crowds of old people and children having difficulty in swallowing.
Description
Technical field
The present invention relates to pharmaceutical formulations field, disclose a kind of sublingual film of Zolpidemtar Trate and preparation method thereof, this wine
The sublingual film of stone acid zolpidem is by Zolpidemtar Trate, macromolecule filming material, plasticizer, penetrating agent, flavouring and other auxiliary materials
Composition；After adding penetrating agent, main ingredient substantially increases through the speed of the outer hypoglossis mucous membrane of animal body.The feature of this formulation is that disintegration is fast
Speed, it is not necessary to take with water and Compliance is good, is better than major part oral solid formulation, is particularly suited for dysphagia, old
The crowd such as people and children.
Background technology
Insomnia is one of common clinical disease, though being not belonging to critical illness, but hinders people's normal life, works, learns
And health, and can increase the weight of or induce the illnesss such as palpitaition, the obstruction of qi in the chest, dizziness, headache, apoplexy.Obstinate insomnia, brings to patient
Long-term misery, even forms the dependence to sleeping medicine, and the sleeping medicine of long-term taking can cause iatrogenic disease.Relevant
Data display Chinese adult insomnia rate reaches 38.2%, and sleep quality causes anxiety.
Zolpidemtar Trate is third generation sedative hypnotic drug, and sedative-hypnotic effect is very strong, is mainly used in the short of insomnia
Phase treats.Oral administration biaavailability is 70%, and shows linear dynamics in the range of therapeutic dose, oral latter 0.3～3 hour
Blood concentration peaking.Eliminating the half-life, average out to 2.4 hours (0.7～3.5), effect can maintain 6 hours.Plasma protein is tied
Conjunction rate is 92.5% ± 0.1%.The first pass effect of liver is 35%.Repeat to take medicine and do not change protein binding rate, show this product and its
Metabolin lacks competition to binding site.The apparent volume of distribution of adult is 0.54 ± 0.2L/kg.The elderly is down to 0.34 ±
0.052L/kg.All metabolins are the most inactive, and discharged by (37%) in (56%) in urine and ight soil.Test shows zolpidem
It is the most dialyzable.
This medicine is developed by Sythelabo company of France, within 1988, lists in France.China starts import in nineteen ninety-five
Zolpidem.Current domestic listing have tablet and dispersible tablet.By patent search, the formulation patent about zolpidem has sustained release double
The formulations such as synusia, pulse controlled release drug administration, oral spray, sustained release pellet, film.Patent document CN101849926B discloses wine
Stone acid zolpidem film (preparation method).Patent document CN105581991A disclose a kind of Zolpidemtar Trate sublingual tablet and
Preparation method
The present invention is compared with above-mentioned Zolpidem tartrate film, and its superiority is creatively rationally to add appropriate rush to ooze
Agent, improves its main ingredient and passes through speed and the transmitance of hypoglossis mucous membrane, substantially increase the advantage of this formulation.The present invention is with above-mentioned
Sublingual tablet is compared, and more embodies the film peculiar advantage to tablet, i.e. disintegration rapidly, it is not necessary to take with water and take medicine and comply with
Property good, be better than major part oral solid formulation, be particularly suited for the crowds such as dysphagia, old man and children.
Summary of the invention
The technical problem to be solved is to provide the preparation method of the sublingual film of a kind of Zolpidemtar Trate.
For solving above-mentioned technical problem, the technical solution used in the present invention is:
First the present invention discloses a kind of sublingual film of Zolpidemtar Trate, it is characterised in that include following component: winestone
Acid zolpidem, macromolecule filming material, mould agent, penetrating agent, flavouring and other auxiliary material.
The sublingual film of Zolpidemtar Trate of the present invention, it is characterised in that the percentage of each component is:
The percentage sum of above-mentioned component is 100%.
The sublingual film of described Zolpidemtar Trate, it is characterised in that the percentage of each component is:
The percentage sum of above-mentioned component is 100%.
The sublingual film of Zolpidemtar Trate of the present invention, optimum prescription is Zolpidemtar Trate 24%, macromolecule filming
Material 40%, plasticizer 17%, penetrating agent 8%, flavouring 5%～11%, other auxiliary material 0%～6%.
Described macromolecule filming material is polyvinyl alcohol (PVA), hydroxypropyl methyl cellulose (HPMC), pulullan polysaccharide
(Pullulan), one or more in xanthans, Arabic gum, polyvinylpyrrolidone, sodium alginate and maltodextrin；Excellent
Elect HPMC-E15 as；
Described plasticizer is one or more in glycerine, Tween 80, polyethylene glycol, sorbierite；It is preferably polyethylene glycol
400；
Described penetrating agent is edetate, sodium salicylate, lauryl sodium sulfate, polyoxyethylene lauryl base ester, deoxidation
One or more in sodium taurocholate, oleic acid, octanoic acid, azone；It is preferably sodium salicylate；
Described flavouring selected from sweetener and or aromatic；
Described sweetener has that saccharin or saccharin sodium, Sucralose, Abbas be sweet, sucrose, Radix Glycyrrhizae propylhomoserin, Steviosin, red
In fresh sugar alcohol one or more, preferably Sucralose；
Other auxiliary materials described include filler, pigment, antioxidant or preservative；
Also include selected from by tree oil, orange oil, peppermint oil, peppermint oil dementholized or the aromatic of menthol.
The preparation method of the sublingual film of Zolpidemtar Trate of the present invention, it is characterised in that step is as follows:
Zolpidemtar Trate is dissolved in the water of 3～10 times amount the solution obtaining homogeneous transparent, adds macromolecule filming material
Material, plasticizer, penetrating agent, flavouring and other auxiliary materials, stir into uniform slurries, deaeration, plastic film mulch, and 40～80 DEG C are dried, thick
Degree 80um ± 5, cut.
In described technique, the weight ratio of Zolpidemtar Trate and water be 1:8 be optimum；
The sublingual film of described Zolpidemtar Trate, it is characterised in that the product that the method prepares is in 37 DEG C of water in 45 seconds
Can completely dissolve, main ingredient Zolpidemtar Trate is spread out；
The sublingual film of described Zolpidemtar Trate, it is characterised in that finished product film can have certain toughness and tensile strength,
Its tensile strength is more than 5.8PMa.
The index evaluating sublingual film mainly has outward appearance, dissolves time limit, tensile strength and mouthfeel.Domestic at present to dissolving the time limit
There is no a unified requirement, generally less than 60 seconds, and macromolecule filming material consumption is the fewest, water-soluble plasticizer consumption is the most, its
Being disintegrated the fastest, premise is film forming can i.e. to have certain tensile strength；Flavouring is the most then crossed sweet or slightly bitter, crosses flavoring at least and fails to understand
Aobvious.So filmogen, plasticizer and flavouring are good with medicinal active ingredient holding the most then flavoring, tensile strength
Moderate, disintegration is fast.
Accompanying drawing illustrates:
Fig. 1, external pig hypoglossis mucous membrane permeability test
Detailed description of the invention
Below in conjunction with specific embodiment further describe the present invention, advantages of the present invention and feature will be with describe and
Apparent.It should be understood that described embodiment is only exemplary, the scope of the present invention is not constituted any restriction.This area
Skilled artisans appreciated that, lower without departing from the spirit and scope of the present invention can to the details of technical solution of the present invention and
Form is modified or replaces, but these amendments or replacement each fall within protection scope of the present invention.
The preparation of the sublingual film of embodiment 1 Zolpidemtar Trate
Totally 5000, specification 5mg, prescription is as follows:
Zolpidemtar Trate is dissolved in 200g water the solution obtaining homogeneous transparent, adds macromolecule filming material, plasticising
Agent, penetrating agent, flavouring and other auxiliary materials, stir into uniform slurries, deaeration, film, and 40～80 DEG C are dried, cut.
This film outward appearance is preferable, and milky, hand is touched smooth, thickness 80um ± 5, tensile strength 10.5 ± 2MPa, and mouthfeel is micro-
Sweet, dissolve time limit 22s.
The preparation of the sublingual film of embodiment 2 Zolpidemtar Trate
Totally 5000, specification 5mg, prescription is as follows:
Zolpidemtar Trate is dissolved in 200g water the solution obtaining homogeneous transparent, adds macromolecule filming material, plasticising
Agent, penetrating agent, flavouring and other auxiliary materials, stir into uniform slurries, deaeration, film, and 40～80 DEG C are dried, cut.
This film outward appearance is preferable, and milky, hand is touched smooth, thickness 80um ± 5, tensile strength 7.9 ± 2MPa, and mouthfeel is micro-
Sweet, dissolve time limit 24s.
The preparation of the sublingual film of embodiment 3 Zolpidemtar Trate
Totally 5000, specification 5mg, prescription is as follows:
Zolpidemtar Trate is dissolved in 200g water the solution obtaining homogeneous transparent, adds macromolecule filming material, plasticising
Agent, penetrating agent, flavouring and other auxiliary materials, stir into uniform slurries, deaeration, film, and 40～80 DEG C are dried, cut.
This film outward appearance is preferable, and milky, hand is touched smooth, thickness 80um ± 5, tensile strength 9.6 ± 2MPa, and mouthfeel is micro-
Sweet, dissolve time limit 32s.
The preparation of the sublingual film of embodiment 4 Zolpidemtar Trate
Totally 5000, specification 5mg, prescription is as follows:
Zolpidemtar Trate is dissolved in 200g water the solution obtaining homogeneous transparent, adds macromolecule filming material, plasticising
Agent, penetrating agent, flavouring and other auxiliary materials, stir into uniform slurries, deaeration, film, and 40～80 DEG C are dried, cut.
This film outward appearance is preferable, and milky, hand is touched smooth, thickness 80um ± 5, tensile strength 10.8 ± 2MPa, and mouthfeel is micro-
Sweet, dissolve time limit 24s.
The preparation of the sublingual film of embodiment 5 Zolpidemtar Trate
Totally 5000, specification 5mg, prescription is as follows:
Zolpidemtar Trate is dissolved in 200g water the solution obtaining homogeneous transparent, adds macromolecule filming material, plasticising
Agent, penetrating agent, flavouring and other auxiliary materials, stir into uniform slurries, deaeration, film, and 40～80 DEG C are dried, cut.
This film outward appearance is preferable, and milky, hand is touched smooth, thickness 80um ± 5, tensile strength 11.2 ± 2MPa, and mouthfeel is light
And sweetless, dissolve time limit 24s.
The preparation of the sublingual film of embodiment 6 Zolpidemtar Trate
Totally 5000, specification 5mg, prescription is as follows:
Zolpidemtar Trate is dissolved in 200g water the solution obtaining homogeneous transparent, adds macromolecule filming material, plasticising
Agent, penetrating agent, flavouring and other auxiliary materials, stir into uniform slurries, deaeration, film, and 40～80 DEG C are dried, cut.
This film outward appearance is preferable, and milky, hand is touched smooth, thickness 80um ± 5, tensile strength 30.5 ± 2MPa, and mouthfeel is micro-
Sweet, dissolve time limit 45s.
The preparation of the sublingual film of embodiment 7 Zolpidemtar Trate
Totally 5000, specification 5mg, prescription is as follows:
Zolpidemtar Trate is dissolved in 250g water the solution obtaining homogeneous transparent, adds macromolecule filming material, plasticising
Agent, penetrating agent, flavouring and other auxiliary materials, stir into uniform slurries, deaeration, film, and 40～80 DEG C are dried, cut.
The coating liquid that this technique prepares is diluter, and film forming agent outward appearance is general, milky, and hand is touched smooth, thickness 80um ± 5, anti-
Tensile strength 10.8 ± 2MPa, mouthfeel is micro-sweet, dissolves time limit 25s.
The preparation of the sublingual film of embodiment 8 Zolpidemtar Trate
Totally 5000, specification 5mg, prescription is as follows:
Zolpidemtar Trate is dissolved in 200g water the solution obtaining homogeneous transparent, adds macromolecule filming material, plasticising
Agent, penetrating agent, flavouring and other auxiliary materials, stir into uniform slurries, deaeration, film, and 40～80 DEG C are dried, cut.
This film outward appearance is preferable, and milky, hand is touched smooth, thickness 80um ± 5, tensile strength 11.5 ± 2MPa, and mouthfeel is micro-
Sweet, dissolve time limit 26s.
The preparation of the sublingual film of embodiment 9 Zolpidemtar Trate
Totally 5000, specification 5mg, prescription is as follows:
Zolpidemtar Trate is dissolved in 75g water the solution obtaining homogeneous transparent, adds macromolecule filming material, plasticising
Agent, penetrating agent, flavouring and other auxiliary materials, stir into uniform slurries, deaeration, plastic film mulch, and 40～80 DEG C are dried, cut.
The coating liquid relatively thickness that this technique prepares, film forming agent outward appearance is general, milky, and hand is touched smooth, thickness 80um ± 5,
Tensile strength 10.5 ± 2MPa, mouthfeel is micro-sweet, dissolves time limit 24s.
The preparation of the sublingual film of embodiment 10 Zolpidemtar Trate
Totally 5000, specification 5mg, prescription is as follows:
Zolpidemtar Trate is dissolved in 200g water the solution obtaining homogeneous transparent, adds macromolecule filming material, plasticising
Agent, penetrating agent, flavouring and other auxiliary materials, stir into uniform slurries, deaeration, plastic film mulch, and 40～80 DEG C are dried, cut.
This film outward appearance is general, and milky, hand touches with granular sensation, thickness 80um ± 5, tensile strength 5.8 ± 2MPa, mouthfeel
Micro-sweet, dissolve time limit 20s.
Embodiment 11 external pig hypoglossis mucous membrane permeability test (embodiment 1, embodiment 2 and embodiment 8) is from the pig just slaughtered
Taking its hypoglossis mucous membrane in Tou immediately, with normal saline flushing 2～3 times, 37 DEG C ± 2 constant temperature are standby.
Franz solid diffusion cell is used to carry out external hypoglossis mucous membrane permeability test.By expansion reservoir, pig hypoglossis mucous membrane is fixed,
The outer layer of smooth mucosal is towards supply pool, and the internal layer of fold is towards water-accepting tank.37 DEG C ± 2 water-baths, mixing speed 600rpm, thoroughly glue
Membrane area 0.556 square centimeter, reception tank volume 1.5mL, receive the physiological salt liquid that liquid is 0.1mol/L hydrochloric acid.
Prepared embodiment 1, embodiment 2 and the sublingual film of embodiment 8 are respectively placed on pig hypoglossis mucous membrane, timing sampling
1mL, and supplement the blank reception liquid of 37 DEG C ± 2.Sample high performance liquid chromatograph is analyzed with suitable detection method, knot
Fruit sees accompanying drawing explanation.
Claims (8)
1. the sublingual film of Zolpidemtar Trate, it is characterised in that include following component: Zolpidemtar Trate, macromolecule become
Membrane material, mould agent, penetrating agent, flavouring and other auxiliary material.
2. according to the sublingual film of the Zolpidemtar Trate described in claim 1, it is characterised in that the percentage of each component is:
The percentage sum of above-mentioned component is 100%.
3. according to the sublingual film of the Zolpidemtar Trate described in claim 2, it is characterised in that the percentage of each component is:
The percentage sum of above-mentioned component is 100%.
4., according to the sublingual film of the Zolpidemtar Trate described in claims 1 to 3, optimum prescription is Zolpidemtar Trate 24%, high
Molecular film-forming material 40%, plasticizer 17%, penetrating agent 8%, flavouring 5%～11%, other auxiliary material 0%～6%；Described height
Molecular film-forming material is polyvinyl alcohol (PVA), hydroxypropyl methyl cellulose (HPMC), pulullan polysaccharide (Pullulan), xanthan
One or more in glue, Arabic gum, polyvinylpyrrolidone, sodium alginate and maltodextrin；It is preferably HPMC-E15；Institute
Stating plasticizer is one or more in glycerine, Tween 80, polyethylene glycol, sorbierite；It is preferably PEG400；Described rush
Penetration enhancer is edetate, sodium salicylate, lauryl sodium sulfate, polyoxyethylene lauryl base ester, NaTDC, oleic acid, pungent
One or more in acid, azone；It is preferably sodium salicylate；Described flavouring selected from sweetener and or aromatic；Described
Sweetener have that saccharin or saccharin sodium, Sucralose, Abbas be sweet, a kind of in sucrose, Radix Glycyrrhizae propylhomoserin, Steviosin, erythrose alcohol
Or several, preferably Sucralose；Other auxiliary materials described include filler, pigment, antioxidant or preservative；Also include being selected from
By tree oil, orange oil, peppermint oil, peppermint oil dementholized or the aromatic of menthol.
5. according to the preparation method of the sublingual film of Zolpidemtar Trate described in Claims 1-4 any one, it is characterised in that step
Rapid as follows:
Zolpidemtar Trate is dissolved in the water of 3～10 times amount the solution obtaining homogeneous transparent, adds macromolecule filming material, increasing
Moulding agent, penetrating agent, flavouring and other auxiliary materials, stir into uniform slurries, deaeration, film, 40～80 DEG C are dried, thickness 80um
± 5, cut.
The most according to claim 5 in technique, the weight ratio of Zolpidemtar Trate and water be 1:8 be optimum.
The sublingual film of Zolpidemtar Trate the most according to claims 1 to 6, it is characterised in that the product that the method prepares exists
37 DEG C of water can dissolve in 45 seconds completely, main ingredient Zolpidemtar Trate is spread out.
The sublingual film of Zolpidemtar Trate the most according to claims 1 to 7, it is characterised in that finished product film can have certain
Toughness and tensile strength, its tensile strength is more than 5.8PMa.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610517942.6A CN105902524A (en) | 2016-06-30 | 2016-06-30 | Sublingual zolpidem tartrate pellicle and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610517942.6A CN105902524A (en) | 2016-06-30 | 2016-06-30 | Sublingual zolpidem tartrate pellicle and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105902524A true CN105902524A (en) | 2016-08-31 |
Family
ID=56754270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610517942.6A Pending CN105902524A (en) | 2016-06-30 | 2016-06-30 | Sublingual zolpidem tartrate pellicle and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105902524A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107468672A (en) * | 2017-07-28 | 2017-12-15 | 合肥华方医药科技有限公司 | A kind of silaenafil oral quick-dissolving film preparation and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101849926A (en) * | 2009-06-12 | 2010-10-06 | 上海现代药物制剂工程研究中心有限公司 | Zolpidem tartrate film |
| CN103356509A (en) * | 2012-03-29 | 2013-10-23 | 刘毅佳 | Film agent containing zolpidem serving as main active component |
| CN104884041A (en) * | 2012-09-28 | 2015-09-02 | 法玛费尔姆有限责任公司 | Orodispersible films having quick dissolution times for therapeutic and food use |
-
2016
- 2016-06-30 CN CN201610517942.6A patent/CN105902524A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101849926A (en) * | 2009-06-12 | 2010-10-06 | 上海现代药物制剂工程研究中心有限公司 | Zolpidem tartrate film |
| CN103356509A (en) * | 2012-03-29 | 2013-10-23 | 刘毅佳 | Film agent containing zolpidem serving as main active component |
| CN104884041A (en) * | 2012-09-28 | 2015-09-02 | 法玛费尔姆有限责任公司 | Orodispersible films having quick dissolution times for therapeutic and food use |
Non-Patent Citations (2)
| Title |
|---|
| VINAY UMESH RAO,ET AL.: "Development and optimization of orally dissolving film of zolpidem tarterate", 《AMERICAN JOURNAL OF ADVANCED DRUG DELIVERY》 * |
| 程刚: "《生物药剂学》", 31 August 2015, 中国医药科技出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107468672A (en) * | 2017-07-28 | 2017-12-15 | 合肥华方医药科技有限公司 | A kind of silaenafil oral quick-dissolving film preparation and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hua | Advances in nanoparticulate drug delivery approaches for sublingual and buccal administration | |
| EP2961377B1 (en) | Enhanced stability of novel liquid compositions | |
| BRPI0708068A2 (en) | collapsible buccal films | |
| JP2002534463A (en) | COMPOSITIONS WITH IMPROVED ACTIVITY OF ACTIVATORS | |
| JP5715400B2 (en) | Loxoprofen-containing pharmaceutical composition | |
| BRPI0906648A2 (en) | edible film strips for immediate release of active ingredients | |
| BRPI0714399A2 (en) | oral liquid pharmaceutical composition, method of treating a mammal in need of treatment; and aqueous, oral pharmaceutical composition | |
| Upreti et al. | Formulation and evaluation of mouth dissolving films of paracetamol | |
| CN104784157B (en) | A kind of montelukast oral membrane agent of stabilization | |
| Dhiman et al. | Transbuccal delivery of 5-fluorouracil: permeation enhancement and pharmacokinetic study | |
| CN103263402A (en) | Water-drinking-free oral drug composition and preparation method thereof | |
| AU771478B2 (en) | Compositions having improved stability | |
| CN1346270A (en) | Compositions having improved stability | |
| CN102940616A (en) | Ambroxol hydrochloride oral cavity dispersion membrane agent | |
| CN103860523A (en) | Chlorphenamine maleate oral fast dissolving film and preparation method thereof | |
| CN105902524A (en) | Sublingual zolpidem tartrate pellicle and preparation method thereof | |
| CN103393624B (en) | Montelukast sodium membrane-shape preparation | |
| CN105963280B (en) | A kind of voglibose oral instant membrane and preparation method thereof | |
| CN106074457A (en) | A kind of Olopatadine hydrochloride oral instant membrane and preparation method thereof | |
| JP6050564B2 (en) | Film-form preparation | |
| CN102935078A (en) | Ibuprofen oral dispersing film agent | |
| JP2013032351A (en) | Herbal medicine or crude medicine formulation and method for producing the same | |
| CN102048711A (en) | Granisetron membrane preparation and preparation method | |
| CN105919982A (en) | Racecadotril oral fast dissolving film and preparation method thereof | |
| CN103349657B (en) | Risperidone film-shaped preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160831 |